ESP対腹腔鏡下胆嚢摘出術における鎮痛のエクソラブロック
腹腔鏡下胆嚢摘出術におけるエレクター脊髄面(ESP)と外斜面および直腸腹部平面(exora)ブロックの有効性の比較
Patients undergoing laparoscopic cholecystectomy may experience moderate to severe postoperative pain. Effective postoperative analgesia enhances patient comfort and accelerates recovery. This study aims to compare the effects of Erector Spinae Plane (ESP) and External Oblique and Rectus Abdominis Plane (EXORA) blocks on postoperative pain management and analgesic consumption.
The study is designed as a prospective, randomized, double-blind trial. Patients will be randomly assigned to groups, and both practitioners and evaluators will be blinded to group assignments. Our hypothesis is that the EXORA block will provide superior analgesia and require less analgesic consumption compared to the ESP block. The results will be assessed in terms of postoperative pain management, patient comfort, and additional analgesic requirements.
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
研究の種類
研究の種類
入学 (実際)
入学
段階
段階
- 適用できない
連絡先と場所
研究場所
-
-
-
Kütahya、トルコ(Türkiye)
- Kütahya City Hospital
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
Age between 18 and 65 years
Undergoing elective laparoscopic cholecystectomy
Classified as American Society of Anesthesiologists (ASA) physical status I to III
Providing written informed consent
Exclusion Criteria:
Known allergy or hypersensitivity to local anesthetics
Infection or skin lesions at the site of block application
Emergency surgical procedures
Refusal to participate in the study
Uncontrolled arterial hypertension
Uncontrolled diabetes mellitus
Mental retardation
Current use of antidepressant medications
Presence of metabolic disorders
Known bleeding diathesis
Morbid obesity (Body Mass Index > 40 kg/m²)
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:防止
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:ダブル
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
アクティブコンパレータ:Group ESP
The ESP block will be performed approximately 30 minutes before general anesthesia induction following sedation and standard monitoring. All block procedures will be conducted under sterile conditions, with skin preparation using dermol (%70 Isopropyl Alcohol, %2 Chlorhexidine Gluconate) and the ultrasound probe covered with a sterile drape. |
Experienced anesthesiologists with at least five years of expertise in regional anesthesia will perform the blocks under ultrasound guidance. A 4.0-12.0 MHz linear ultrasound probe (Affiniti 50; Philips) will be used. The ESP block will be applied at the T8 level on the right side, using an in-plane approach, while the patient is in a sitting position. The probe will be placed 2-3 cm lateral to the vertebra in a sagittal position to visualize the erector spinae muscle and transverse processes. A 22G, 100 mm block needle (Stimuplex® Ultra, Braun, Germany) will be advanced in a craniocaudal direction. The correct needle position will be confirmed by injecting 0.5-1 mL of isotonic NaCl and observing the spread via hydrodissection. Finally, 0.3 mL/kg of 0.25% bupivacaine will be administered, ensuring cranial and caudal spread of the local anesthetic. |
|
アクティブコンパレータ:Group EXORA
The EXORA block will be performed 30 minutes before general anesthesia induction, following sedation and standard monitoring. |
Experienced anesthesiologists with at least five years of expertise in regional anesthesia will administer the blocks under ultrasound guidance. A 4.0-12.0 MHz linear ultrasound probe will be placed laterally to the xiphoid process on the parasternal line in a sagittal position. The probe will be moved craniocaudally to identify the 6th rib and further advanced caudally to locate the 8th rib. Once the rectus abdominis muscle and 8th costal cartilage are identified, a 22G, 100 mm block needle will be used to administer 0.3 mL/kg of 0.25% bupivacaine. The correct spread of the local anesthetic will be confirmed via ultrasound. |
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Tramadol consumption
時間枠:12 and 24 hours
|
Total tramadol used in the first 12 and 24 hours postoperatively. |
12 and 24 hours
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Visual Analog Scale (VAS) for Pain Assessment
時間枠:30 minutes, 2 hours, 4 hours, 8 hours, 12 hours, and 24 hours after surgery
|
Postoperative pain will be assessed using the Visual Analog Scale (VAS), which ranges from 0 (no pain) to 10 (worst imaginable pain). Higher scores indicate a worse outcome (more pain). Units on a scale (0-10) |
30 minutes, 2 hours, 4 hours, 8 hours, 12 hours, and 24 hours after surgery
|
|
Pinprick Sensory Block Test Results
時間枠:10 minutes, 20 minutes, and 30 minutes after the block, and 30 minutes after surgery
|
Sensory block efficacy will be evaluated using the pinprick test at specified time intervals. The presence or absence of sensory block will be recorded. Binary (Block present / Block absent) |
10 minutes, 20 minutes, and 30 minutes after the block, and 30 minutes after surgery
|
|
Nausea and Vomiting Score (NVS)
時間枠:Within 24 hours after surgery
|
Postoperative nausea and vomiting will be evaluated using the Nausea and Vomiting Scale (NVS), which includes:
|
Within 24 hours after surgery
|
|
Ramsay Sedation Scale (RSS)
時間枠:Within 24 hours after surgery
|
Postoperative sedation will be assessed using the Ramsay Sedation Scale (RSS), which includes:
|
Within 24 hours after surgery
|
|
Additional Analgesic Consumption
時間枠:Within 24 hours after surgery
|
The total amount of additional analgesics administered postoperatively will be recorded. Milligrams (mg) |
Within 24 hours after surgery
|
その他の成果指標
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Total Antiemetic Consumption
時間枠:Within 24 hours after surgery
|
The total amount of antiemetic medication administered within 24 hours postoperatively will be recorded. Milligrams (mg) |
Within 24 hours after surgery
|
協力者と研究者
協力者
協力者
捜査官
捜査官
- 主任研究者:Aycan KURTARANGİL DOĞAN、Kütahya City Hospital
- 主任研究者:Ali Kaynak、Kütahya City Hospital
研究記録日
主要日程の研究
研究開始 (実際)
研究開始
一次修了 (実際)
一次修了
研究の完了 (実際)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
その他の研究ID番号
- KSH-01
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。